US equities |
MU $1,029.00 ▼-0.66% NVDA $229.28 ▼-0.52% SPCX $162.57 ▲+1.25% TSLA $382.70 ▲+2.05% AAPL $336.64 ▼-1.11% MSFT $535.07 ▲+2.38% AMZN $262.43 ▲+3.29% META $718.67 ▼-0.31%
FinancialContent

Latest News about GeoVax, Inc/

Recent news which mentions GeoVax, Inc/

< Previous 1 2 Next >
GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine
Tickers GOVX
Tags GeoVax, Inc/ en/US XNAS:GOVX
From TheNewswire.com - RSS (Media)
GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains
Tickers GOVX
Tags GeoVax, Inc/ en/US XNAS:GOVX
From TheNewswire.com - RSS (Media)
GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation
Tickers GOVX
Tags GeoVax, Inc/ XNAS:GOVX en/US
From TheNewswire.com - RSS (Media)
GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results
Tickers GOVX R
Tags en/US XNAS:GOVX GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025
Tickers GOVX
Tags GeoVax, Inc/ en/US XNAS:GOVX
From TheNewswire.com - RSS (Media)
GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine
Tickers GOVX
Tags GeoVax, Inc/ XNAS:GOVX en/US
From TheNewswire.com - RSS (Media)
GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax to Present at the Emerging Growth Conference on July 16, 2025
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax Highlights Critical Role of Multi-Antigen COVID-19 Vaccines as Nimbus Variant Underscores Persistent and Evolving Public Health Threat
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax Responds to Growing Mpox Threat With Expedited EU Pathway and Platform Aligned to U.S. Biodefense Objectives
Tickers GOVX
Tags en/US XNAS:GOVX GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax to Raise Approximately $6 Million of Gross Proceeds in Public Offering
Tickers GOVX
Tags GeoVax, Inc/ en/US XNAS:GOVX
From TheNewswire.com - RSS (Media)
GeoVax Announces Issuance of Patent Covering Novel Vaccine Construct for Preventing Malaria Infection
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax Comments on FDA Approval of Keytruda(R) in Head and Neck Cancer, Underscoring Potential for Gedeptin(R) Combination Therapy
Tickers GOVX R
Tags GeoVax, Inc/ en/US XNAS:GOVX
From TheNewswire.com - RSS (Media)
GeoVax Highlights Positive Immune Response Results From GEO-CM04S1 in CLL Patients at the European Hematology Association 2025 Meeting
Tickers GOVX
Tags en/US XNAS:GOVX GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax Receives Favorable European Regulatory Guidance Supporting Streamlined Development Pathway for GEO-MVA
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax to Participate in BIO International Convention 2025
Tickers GOVX
Tags GeoVax, Inc/ en/US XNAS:GOVX
From TheNewswire.com - RSS (Media)
GeoVax Responds to WHO's Fourth Declaration of Mpox as a Global Public Health Emergency
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax Announces Upcoming Presentation at the European Hematology Association 2025 Congress Highlighting Positive Immune Response Data for GEO-CM04S1 in CLL Patients
Tickers GOVX
Tags GeoVax, Inc/ en/US XNAS:GOVX
From TheNewswire.com - RSS (Media)
GeoVax Highlights Broad Cross-Protective Immunity of Multi-Antigen COVID-19 Vaccine Candidates at Keystone Symposia
Tickers GOVX
Tags GeoVax, Inc/ XNAS:GOVX en/US
From TheNewswire.com - RSS (Media)
GeoVax to Showcase Innovative COVID 19 Vaccine Data at the Keystone Symposia on Vaccinology
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax Congratulates Bipartisan Senate Action to Onshore Critical Medical Manufacturing
Tickers GOVX
Tags en/US XNAS:GOVX GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax Commends FDA's Shift to Risk-Based COVID-19 Vaccination Guidance
Tickers GOVX
Tags GeoVax, Inc/ en/US XNAS:GOVX
From TheNewswire.com - RSS (Media)
GeoVax Applauds EQUIP-A-Pharma Initiative, Reinforces Commitment to Domestic Vaccine Manufacturing and Biodefense Innovation
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax Reaffirms Urgent Need for Multi-Antigen COVID-19 Vaccines as CDC Shifts Recommendations
Tickers GOVX
Tags XNAS:GOVX en/US GeoVax, Inc/
From TheNewswire.com - RSS (Media)
GeoVax Highlights Dual Protective Potential of GEO-CM04S1 Following Presentation at the AAI Annual Meeting 2025
Tickers GOVX
Tags GeoVax, Inc/ XNAS:GOVX en/US
From TheNewswire.com - RSS (Media)
GeoVax Expands Gedeptin(R) Patent Portfolio
Tickers GOVX R
Tags GeoVax, Inc/ en/US XNAS:GOVX
From TheNewswire.com - RSS (Media)
GeoVax Applauds White House Executive Order Supporting U.S. Pharmaceutical Manufacturing; Highlights Progress in Domestic MVA Vaccine Production
Tickers GOVX
Tags GeoVax, Inc/ XNAS:GOVX en/US
From TheNewswire.com - RSS (Media)
< Previous 1 2 Next >